Interaction of viral oncogenic proteins with the Wnt signaling pathway

Document Type : Review Article


1 Hepatitis Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran

2 Department of Virology, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran

3 Department of English Language, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran

4 Department of Microbiology, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran


It is estimated that up to 20% of all types of human cancers worldwide are attributed to viruses. The genome of oncogenic viruses carries genes that have protein products that act as oncoproteins in cell proliferation and transformation. The modulation of cell cycle control mechanisms, cellular regulatory and signaling pathways by oncogenic viruses, plays an important role in viral carcinogenesis. Different signaling pathways play a part in the carcinogenesis that occurs in a cell. Among these pathways, the Wnt signaling pathway plays a predominant role in carcinogenesis and is known as a central cellular pathway in the development of tumors. There are three Wnt signaling pathways that are well identified, including the canonical or Wnt/β-catenin dependent pathway, the noncanonical or β-catenin-independent planar cell polarity (PCP) pathway, and the noncanonical Wnt/Ca2+ pathway. Most of the oncogenic viruses modulate the canonical Wnt signaling pathway. This review discusses the interaction between proteins of several human oncogenic viruses with the Wnt signaling pathway.


Main Subjects

1. Liao JB. Viruses and human cancer. Yale J Biol Med 2006; 79:115-122.
2. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M, Comparative Risk Assessment collaborating g. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 2005; 366:1784-1793.
3. Alibek K, Irving S, Sautbayeva Z, Kakpenova A, Bekmurzayeva A, Baiken Y, et al. Disruption of Bcl-2 and Bcl-xL by viral proteins as a possible cause of cancer. Infectious agents and cancer 2014; 9:44.
4. Mesri EA, Feitelson MA, Munger K. Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe 2014; 15:266-282.
5. Niller HH, Wolf H, Minarovits J. Viral hit and run-oncogenesis: genetic and epigenetic scenarios. Cancer Lett 2011; 305:200-217.
6. Dreesen O, Brivanlou AH. Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev 2007; 3:7-17.
7. Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis 2008; 4:68-75.
8. Willert K, Nusse R. Wnt proteins. Cold Spring Harb Perspect Biol 2012; 4:a007864.
10. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012; 149:1192-1205.
11. Howe LR, Brown AM. Wnt signaling and breast cancer. Cancer Biol Ther 2004; 3:36-41.
12. Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene 2017; 36:1461-1473.
13. Katano H. [Epstein-Barr virus (EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV, HHV-8)]. Uirusu 2010; 60:237-245.
14. Chen MR. Epstein-barr virus, the immune system, and associated diseases. Front Microbiol 2011; 2: 5.
15. Ma SD TM, Romero-Masters JC, Ranheim EA, Huebner SM, Bristol JA, Delecluse HJ, Kenney SC. Latent Membrane Protein 1 (LMP1) and LMP2A Collaborate To Promote Epstein-Barr Virus-Induced B Cell Lymphomas in a Cord Blood-Humanized Mouse Model but Are Not Essential. J Virol 2017; 91:e01928-01916.
16. Angelova M, Ferris M, Swan KF, McFerrin HE, Pridjian G, Morris CA, et al. Kaposi’s sarcoma-associated herpesvirus G-protein coupled receptor activates the canonical Wnt/beta-catenin signaling pathway. Virol J 2014; 11:218.
17. Fujimuro M, Wu FY, ApRhys C, Kajumbula H, Young DB, Hayward GS, et al. A novel viral mechanism for dysregulation of beta-catenin in Kaposi’s sarcoma-associated herpesvirus latency. Nat Med 2003; 9:300-306.
18. van Zuylen WJ, Rawlinson WD, Ford CE. The Wnt pathway: a key network in cell signalling dysregulated by viruses. Rev Med Virol 2016; 26:340-355.
19. Bornkamm GW. Epstein-Barr virus and the pathogenesis of Burkitt’s lymphoma: more questions than answers. Int J Cancer 2009; 124:1745-1755.
20. Morrison JA, Raab-Traub N. Roles of the ITAM and PY motifs of Epstein-Barr virus latent membrane protein 2A in the inhibition of epithelial cell differentiation and activation of {beta}-catenin signaling. J Virol 2005; 79:2375-2382.
21. Everly DN, Jr., Kusano S, Raab-Traub N. Accumulation of cytoplasmic beta-catenin and nuclear glycogen synthase kinase 3beta in Epstein-Barr virus-infected cells. J Virol 2004; 78:11648-11655.
22. Cha MY, Kim CM, Park YM, Ryu WS. Hepatitis B virus X protein is essential for the activation of Wnt/beta-catenin signaling in hepatoma cells. Hepatology 2004; 39:1683-1693.
23. Ding SL, Yang ZW, Wang J, Zhang XL, Chen XM, Lu FM. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2015; 21:6317-6328.
24. Xie Q, Chen L, Shan X, Shan X, Tang J, Zhou F, et al. Epigenetic silencing of SFRP1 and SFRP5 by hepatitis B virus X protein enhances hepatoma cell tumorigenicity through Wnt signaling pathway. IJC 2014; 135:635-646.
25. Wang R, Sun Q, Wang P, Liu M, Xiong S, Luo J, et al. Notch and Wnt/beta-catenin signaling pathway play important roles in activating liver cancer stem cells. Oncotarget 2016; 7:5754-5768.
26. Daud M, Rana MA, Husnain T, Ijaz B. Modulation of Wnt signaling pathway by hepatitis B virus. Arch virol 2017; 162:2937-2947.
27. Krekulova L, Rehak V, Riley LW. Structure and functions of hepatitis C virus proteins: 15 years after. Folia Microbiol (Praha) 2006; 51:665-680.
28. Wang W, Pan Q, Fuhler GM, Smits R, Peppelenbosch MP. Action and function of Wnt/beta-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma. J Gastroenterol 2017; 52:419-431.
29. Huang H, Fujii H, Sankila A, Mahler-Araujo BM, Matsuda M, Cathomas G, et al. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol 1999; 155:1795-1801.
30. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010; 29:4989-5005.
31. Umer M, Qureshi SA, Hashmi ZY, Raza A, Ahmad J, Rahman M, et al. Promoter hypermethylation of Wnt pathway inhibitors in hepatitis C virus - induced multistep hepatocarcinogenesis. Virol J 2014; 11:117.
32. Quan H, Zhou F, Nie D, Chen Q, Cai X, Shan X, et al. Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition. Oncogene 2014; 33:2826-2835.
33. Rogacki K, Kasprzak A, Stepinski A. Alterations of Wnt/beta-catenin signaling pathway in hepatocellular carcinomas associated with hepatitis C virus. Pol J Pathol 2015; 66:9-21.
34. Lee SY, Song KH, Koo I, Lee K-H, Suh K-S, Kim B-Y. Comparison of pathways associated with hepatitis B-and C-infected hepatocellular carcinoma using pathway-based class discrimination method. Genomics 2012; 99:347-354.
35. Khanizadeh S, Ravanshad M, Hosseini SY, Davoodian P, Zadeh AN, Sabahi F, et al. The possible role of NS3 protease activity of hepatitis C virus on fibrogenesis and miR-122 expression in hepatic stellate cells. Acta Virol 2016; 60:242-248.
36. Khanizadeh S, Ravanshad M, Hosseini SY, Davoodian P, Almasian M, Khanlari Z. The effect of the hepatitis C virus (HCV) NS3 protein on the expression of miR-150, miR-199a, miR-335, miR-194 and miR-27a. Microb Pathog 2017; 110:688-693.
37. Zhang Y, Wei W, Cheng N, Wang K, Li B, Jiang X, et al. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology 2012; 56:1631-1640.
38. Guntaka RV, Padala MK. Interaction of Hepatitis C Viral Proteins with Cellular Oncoproteins in the Induction of Liver Cancer. ISRN Virology 2014; 2014.
39. Li H, Jiang J-D, Peng Z-G. MicroRNA-mediated interactions between host and hepatitis C virus. World J Gastroenterol 2016; 22:1487.
40. Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007; 7:270-280.
41. Tomita M, Tanaka Y, Mori N. MicroRNA miR-146a is induced by HTLV-1 tax and increases the growth of HTLV-1-infected T-cells. Int J Cancer 2012; 130:2300-2309.
42. Ma G, Yasunaga J-i, Fan J, Yanagawa S-i, Matsuoka M. HTLV-1-mediated dysregulation of the Wnt pathways: roles of Tax and HBZ. Retrovirology 2014; 11:P91.
43. Henderson LJ, Al-Harthi L. Role of beta-catenin/TCF-4 signaling in HIV replication and pathogenesis: insights to informing novel anti-HIV molecular therapeutics. J Neuroimmune Pharmacol 2011; 6:247-259.
44. Wortman B, Darbinian N, Sawaya BE, Khalili K, Amini S. Evidence for regulation of long terminal repeat transcription by Wnt transcription factor TCF-4 in human astrocytic cells. J Virol 2002; 76:11159-11165.
45. Weiser K, Barton M, Gershoony D, Dasgupta R, Cardozo T. HIV’s Nef interacts with beta-catenin of the Wnt signaling pathway in HEK293 cells. PLoS One 2013; 8:e77865.
46. Wang Y, Liao J, Tang SJ, Shu J, Zhang W. HIV-1 gp120 Upregulates Brain-Derived Neurotrophic Factor (BDNF) Expression in BV2 Cells via the Wnt/beta-Catenin Signaling Pathway. J Mol Neurosci 2017; 62:199-208.
47. Bello JO, Nieva LO, Paredes AC, Gonzalez AM, Zavaleta LR, Lizano M. Regulation of the Wnt/beta-Catenin Signaling Pathway by Human Papillomavirus E6 and E7 Oncoproteins. Viruses 2015; 7:4734-4755.
48. Bonilla-Delgado J, Bulut G, Liu X, Cortes-Malagon EM, Schlegel R, Flores-Maldonado C, et al. The E6 oncoprotein from HPV16 enhances the canonical Wnt/beta-catenin pathway in skin epidermis in vivo. Mol Cancer Res 2012; 10:250-258.
49. Rampias T, Boutati E, Pectasides E, Sasaki C, Kountourakis P, Weinberger P, et al. Activation of Wnt signaling pathway by human papillomavirus E6 and E7 oncogenes in HPV16-positive oropharyngeal squamous carcinoma cells. Mol Cancer Res 2010; 8:433-443.
50. Rampias T, Psyrri A. Human Papillomavirus (HPV)-Positive Head and Neck Cancer and the Wnt Signaling Pathway.  Molecular Determinants of Head and Neck Cancer: Springer; 2014. p. 215-225.
51. Sominsky S, Kuslansky Y, Shapiro B, Jackman A, Haupt Y, Rosin-Arbesfeld R, et al. HPV16 E6 and E6AP differentially cooperate to stimulate or augment Wnt signaling. Virology 2014; 468:510-523.
52. Fragoso-Ontiveros V, Alvarez-García RM, Contreras-Paredes A, Vaca-Paniagua F, Herrera LA, López-Camarillo C, et al. Gene expression profiles induced by E6 from non-European HPV18 variants reveals a differential activation on cellular processes driving to carcinogenesis. Virology 2012; 432:81-90.
53. Tomaić V. Functional roles of E6 and E7 oncoproteins in HPV-induced malignancies at diverse anatomical sites. Cancers 2016; 8:95.
54. Teo WH, Chen HP, Huang JC, Chan YJ. Human cytomegalovirus infection enhances cell proliferation, migration and upregulation of EMT markers in colorectal cancer-derived stem cell-like cells. Int J Oncol 2017; 51:1415-1426.
55. Bongers G, Maussang D, Muniz LR, Noriega VM, Fraile-Ramos A, Barker N, et al. The cytomegalovirus-encoded chemokine receptor US28 promotes intestinal neoplasia in transgenic mice. J Clin Invest 2010; 120:3969-3978.
56. Ueland T, Rollag H, Hartmann A, Jardine AG, Humar A, Michelsen AE, et al. Secreted Wnt antagonists during eradication of cytomegalovirus infection in solid organ transplant recipients. Am J Transplant 2014; 14:210-215.
57. Mo X, Xu L, Yang Q, Feng H, Peng J, Zhang Y, et al. Microarray profiling analysis uncovers common molecular mechanisms of rubella virus, human cytomegalovirus, and herpes simplex virus type 2 infections in ECV304 cells. Curr Mol Med 2011; 11:481-488.
58. Smith JL, Jeng S, McWeeney SK, Hirsch AJ. A microRNA screen identifies the Wnt signaling pathway as a regulator of the interferon response during flavivirus infection. Journal of virology 2017; 91:e02388-02316.
59. Margaret E. McLaughlin-Drubin  KM. Viruses Associated with Human Cancer. Biochim Biophys Acta 2008; 1782:127–150.
60. Brunori M, Malerba M, Kashiwazaki H, Iggo R. Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway. Journal of virology 2001; 75:2857-2865.
61. Mackey JK, Rigden PM, Green M. Do highly oncogenic group A human adenoviruses cause human cancer? Analysis of human tumors for adenovirus 12 transforming DNA sequences. Proc Natl Acad Sci U S A 1976; 73:4657-4661.
62. Bian L, Wang Y, Liu Q, Xia J, Long J-E. Prediction of signaling pathways involved in enterovirus 71 infection by algorithm analysis based on miRNA profiles and their target genes. Arch Virol 2015; 160:173-182.
63. Ye X, Hemida MG, Qiu Y, Hanson PJ, Zhang HM, Yang D. MiR-126 promotes coxsackievirus replication by mediating cross-talk of ERK1/2 and Wnt/β-catenin signal pathways. Cell Mol Life Sci 2013; 70:4631-4644.
64. Kang D. EBV BART MicroRNAs Target Pro-apoptotic and Anti-Wnt Signaling Genes to Promote Cell Survival and Proliferation 2015.
65. Dow DE, Cunningham CK, Buchanan AM. A Review of Human Herpesvirus 8, the Kaposi’s Sarcoma-Associated Herpesvirus, in the Pediatric Population. J Pediatric Infect Dis Soc 2014; 3:66-76.
66. Konstantinou D, Deutsch M. The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management. Ann Gastroenterol 2015; 28:221-228.
68. Ravanshad M, Sabahi F, Falahi S, Kenarkoohi A, Amini-Bavil-Olyaee S, Hosseini SY, et al. Prediction of hepatitis B virus lamivudine resistance based on YMDD sequence data using an artificial neural network model. Hepat Mon 2011; 11:108-113.
69. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11:97-107.
70. Kew MC. Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J Gastroenterol Hepatol 2011; 26 Suppl 1:144-152.
71. Neuveut C, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol 2010; 52:594-604.
72. Li YW, Yang FC, Lu HQ, Zhang JS. Hepatocellular carcinoma and hepatitis B surface protein. World J Gastroenterol 2016; 22:1943-1952.
73. Yin Y, Li F, Li S, Cai J, Shi J, Jiang Y. TLR4 Influences Hepatitis B Virus Related Hepatocellular Carcinoma by Regulating the Wnt/beta-Catenin Pathway. Cell Physiol Biochem 2017; 42:469-479.
74. Vilchez V, Turcios L, Marti F, Gedaly R. Targeting Wnt/beta-catenin pathway in hepatocellular carcinoma treatment. World J Gastroenterol 2016; 22:823-832.
75. Suarez MI, Uribe D, Jaramillo CM, Osorio G, Perez JC, Lopez R, et al. Wnt/beta-catenin signaling pathway in hepatocellular carcinomas cases from Colombia. Ann Hepatol 2015; 14:64-74.
76. Tien LT, Ito M, Nakao M, Niino D, Serik M, Nakashima M, et al. Expression of beta-catenin in hepatocellular carcinoma. World J Gastroenterol 2005; 11:2398-2401.
77. Lau CC, Sun T, Ching AK, He M, Li JW, Wong AM, et al. Viral-human chimeric transcript predisposes risk to liver cancer development and progression. Cancer Cell 2014; 25:335-349.
78. Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, et al. Hepatitis C virus infection. Nat Rev Dis Primers 2017; 3:17006.
79. Liu J, Wang Z, Tang J, Tang R, Shan X, Zhang W, et al. Hepatitis C virus core protein activates Wnt/β-catenin signaling through multiple regulation of upstream molecules in the SMMC-7721 cell line. Arch Virol 2011; 156:1013-1023.
80. Park CY, Choi SH, Kang SM, Kang JI, Ahn BY, Kim H, et al. Nonstructural 5A protein activates beta-catenin signaling cascades: implication of hepatitis C virus-induced liver pathogenesis. J Hepatol 2009; 51:853-864.
81. Duesberg PH. Retroviruses as carcinogens and pathogens: expectations and reality. Cancer Res 1987; 47:1199-1220.
82. Weiss RA. The discovery of endogenous retroviruses. Retrovirology 2006; 3:67.
83. Chen Y, Williams V, Filippova M, Filippov V, Duerksen-Hughes P. Viral carcinogenesis: factors inducing DNA damage and virus integration. Cancers 2014; 6:2155-2186.
84. Braoudaki M, Tzortzatou-Stathopoulou F. Tumorigenesis related to retroviral infections. J Infect Dev Countr 2011; 5:751-758.
85. Goncalves DU, Proietti FA, Ribas JG, Araujo MG, Pinheiro SR, Guedes AC, et al. Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev 2010; 23:577-589.
86. Taylor GP, Matsuoka M. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene 2005; 24:6047-6057.
87. Grassmann R, Aboud M, Jeang KT. Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene 2005; 24:5976-5985.
88.Currer R, Van Duyne R, Jaworski E, Guendel I, Sampey G, Das R, et al. HTLV tax: a fascinating multifunctional co-regulator of viral and cellular pathways. Front Microbiol 2012; 3:406.
90. Tomita M, Kikuchi A, Akiyama T, Tanaka Y, Mori N. Human T-cell leukemia virus type 1 tax dysregulates beta-catenin signaling. J Virol 2006; 80:10497-10505.
91. Zhou F, Xue M, Qin D, Zhu X, Wang C, Zhu J, et al. HIV-1 Tat promotes Kaposi’s sarcoma-associated herpesvirus (KSHV) vIL-6-induced angiogenesis and tumorigenesis by regulating PI3K/PTEN/AKT/GSK-3beta signaling pathway. PLoS One 2013; 8:e53145.
92. Carbone A, Gloghini A. AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol 2005; 130:662-670.
93. Carbone A, Gloghini A, Serraino D, Spina M. HIV-associated Hodgkin lymphoma. Curr Opin HIV AIDS 2009; 4:3-10.
94. Han Y, Lin YB, An W, Xu J, Yang HC, O’Connell K, et al. Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell Host Microbe 2008; 4:134-146.
95. De Oliveira DE. DNA viruses in human cancer: an integrated overview on fundamental mechanisms of viral carcinogenesis. Cancer letters 2007; 247:182-196.
96. Arhel N, Kirchhoff F. Host proteins involved in HIV infection: new therapeutic targets. Biochim Biophys Acta 2010; 1802:313-321.
97. Wilen CB, Tilton JC, Doms RW. HIV: cell binding and entry. Cold Spring Harb Perspect Med 2012; 2.
98. Craig HM, Pandori MW, Guatelli JC. Interaction of HIV-1 Nef with the cellular dileucine-based sorting pathway is required for CD4 down-regulation and optimal viral infectivity. Proc Natl Acad Sci U S A 1998; 95:11229-11234.
99. Chen K-C, Wang T-Y, Chan C-h. Associations between HIV and human pathways revealed by protein-protein interactions and correlated gene expression profiles. PLoS One 2012; 7:e34240.
100. Al-Harthi L. Interplay between Wnt/β-catenin signaling and HIV: virologic and biologic consequences in the CNS. J Neuroimmune Pharm 2012; 7:731-739.
102. Zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology 2009; 384:260-265.
103. Tomaic V. Functional Roles of E6 and E7 Oncoproteins in HPV-Induced Malignancies at Diverse Anatomical Sites. Cancers (Basel) 2016; 8: 95.
104. Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular biology and disease association. Rev Med Virol 2015; 25:2-23.
105. Chen J. Signaling pathways in HPV-associated cancers and therapeutic implications. Rev Med Virol 2015; 25 Suppl 1:24-53.
107. Vancikova Z, Dvorak P. Cytomegalovirus infection in immunocompetent and immunocompromised individuals--a review. Curr Drug Targets Immune Endocr Metabol Disord 2001; 1:179-187.
108. Angelova M, Zwezdaryk K, Ferris M, Shan B, Morris CA, Sullivan DE. Human cytomegalovirus infection dysregulates the canonical Wnt/beta-catenin signaling pathway. PLoS Pathog 2012; 8:e1002959.
109. Ghebremedhin B. Human adenovirus: Viral pathogen with increasing importance. Eur J Microbiol Immunol 2014; 4:26-33.